Cargando…

Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff

BACKGROUND: The US federal regulations allow pharmacy administration and dispensing of methadone for opioid use disorder (PADMOUD) to increase the capability of opioid treatment programs (OTPs) in providing methadone maintenance treatment (MMT) for opioid use disorder (OUD) as part of a medication u...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Li-Tzy, Mannelli, Paolo, John, William S., Anderson, Alyssa, Schwartz, Robert P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496162/
https://www.ncbi.nlm.nih.gov/pubmed/37697326
http://dx.doi.org/10.1186/s13011-023-00563-w
_version_ 1785105049183059968
author Wu, Li-Tzy
Mannelli, Paolo
John, William S.
Anderson, Alyssa
Schwartz, Robert P.
author_facet Wu, Li-Tzy
Mannelli, Paolo
John, William S.
Anderson, Alyssa
Schwartz, Robert P.
author_sort Wu, Li-Tzy
collection PubMed
description BACKGROUND: The US federal regulations allow pharmacy administration and dispensing of methadone for opioid use disorder (PADMOUD) to increase the capability of opioid treatment programs (OTPs) in providing methadone maintenance treatment (MMT) for opioid use disorder (OUD) as part of a medication unit. However, there is a lack of research data from both pharmacy and OTP staff to inform the implementation of PADMOUD. METHODS: Staff of a pharmacy (n = 8) and an OTP (n = 9) that participated in the first completed US trial on PADMOUD through electronic prescribing for methadone (parent study) were recruited to participate in this qualitative interview study to explore implementation-related factors for PADMOUD. Each interview was recorded and transcribed verbatim. NVivo was used to help identify themes of qualitative interview data. The Promoting Action on Research Implementation in Health Services (PARIHS) framework was used to guide the coding and interpretation of data. RESULTS: Six pharmacy staff and eight OTP staff (n = 14) completed the interview. Results based on PARIHS domains were summarized, including evidence, context, and facilitation domains. Participants perceived benefits of PADMOUD for patients, pharmacies, OTPs, and payers. PADMOUD was considered to increase access for stable patients, provide additional patient service opportunities and revenues for pharmacies/pharmacists, enhance the capability of OTPs to treat more new patients, and reduce patients’ cost when receiving medication at a pharmacy relative to an OTP. Both pharmacy and OTP staff were perceived to be supportive of the implementation of PADMOUD. Pharmacy staff/pharmacists were perceived to need proper training on addiction and methadone as well as a protocol of PADMOUD to conduct PADMOUD. Facilitators include having thought leaders to guide the operation, a certification program to ensure proper training of pharmacy staff/pharmacist, having updated pharmacy service software or technology to streamline the workflow of delivering PADMOUD and inventory management, and reimbursement for pharmacists. CONCLUSION: This study presents the first findings on perspectives of PADMOUD from both staff of a community pharmacy and an OTP in the US. Finding on barriers and facilitators are useful data to guide the development of strategies to implement PADMOUD to help address the US opioid crisis.
format Online
Article
Text
id pubmed-10496162
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104961622023-09-13 Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff Wu, Li-Tzy Mannelli, Paolo John, William S. Anderson, Alyssa Schwartz, Robert P. Subst Abuse Treat Prev Policy Research BACKGROUND: The US federal regulations allow pharmacy administration and dispensing of methadone for opioid use disorder (PADMOUD) to increase the capability of opioid treatment programs (OTPs) in providing methadone maintenance treatment (MMT) for opioid use disorder (OUD) as part of a medication unit. However, there is a lack of research data from both pharmacy and OTP staff to inform the implementation of PADMOUD. METHODS: Staff of a pharmacy (n = 8) and an OTP (n = 9) that participated in the first completed US trial on PADMOUD through electronic prescribing for methadone (parent study) were recruited to participate in this qualitative interview study to explore implementation-related factors for PADMOUD. Each interview was recorded and transcribed verbatim. NVivo was used to help identify themes of qualitative interview data. The Promoting Action on Research Implementation in Health Services (PARIHS) framework was used to guide the coding and interpretation of data. RESULTS: Six pharmacy staff and eight OTP staff (n = 14) completed the interview. Results based on PARIHS domains were summarized, including evidence, context, and facilitation domains. Participants perceived benefits of PADMOUD for patients, pharmacies, OTPs, and payers. PADMOUD was considered to increase access for stable patients, provide additional patient service opportunities and revenues for pharmacies/pharmacists, enhance the capability of OTPs to treat more new patients, and reduce patients’ cost when receiving medication at a pharmacy relative to an OTP. Both pharmacy and OTP staff were perceived to be supportive of the implementation of PADMOUD. Pharmacy staff/pharmacists were perceived to need proper training on addiction and methadone as well as a protocol of PADMOUD to conduct PADMOUD. Facilitators include having thought leaders to guide the operation, a certification program to ensure proper training of pharmacy staff/pharmacist, having updated pharmacy service software or technology to streamline the workflow of delivering PADMOUD and inventory management, and reimbursement for pharmacists. CONCLUSION: This study presents the first findings on perspectives of PADMOUD from both staff of a community pharmacy and an OTP in the US. Finding on barriers and facilitators are useful data to guide the development of strategies to implement PADMOUD to help address the US opioid crisis. BioMed Central 2023-09-11 /pmc/articles/PMC10496162/ /pubmed/37697326 http://dx.doi.org/10.1186/s13011-023-00563-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wu, Li-Tzy
Mannelli, Paolo
John, William S.
Anderson, Alyssa
Schwartz, Robert P.
Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff
title Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff
title_full Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff
title_fullStr Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff
title_full_unstemmed Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff
title_short Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff
title_sort pharmacy-based methadone treatment in the us: views of pharmacists and opioid treatment program staff
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496162/
https://www.ncbi.nlm.nih.gov/pubmed/37697326
http://dx.doi.org/10.1186/s13011-023-00563-w
work_keys_str_mv AT wulitzy pharmacybasedmethadonetreatmentintheusviewsofpharmacistsandopioidtreatmentprogramstaff
AT mannellipaolo pharmacybasedmethadonetreatmentintheusviewsofpharmacistsandopioidtreatmentprogramstaff
AT johnwilliams pharmacybasedmethadonetreatmentintheusviewsofpharmacistsandopioidtreatmentprogramstaff
AT andersonalyssa pharmacybasedmethadonetreatmentintheusviewsofpharmacistsandopioidtreatmentprogramstaff
AT schwartzrobertp pharmacybasedmethadonetreatmentintheusviewsofpharmacistsandopioidtreatmentprogramstaff